Skip to main content
Have a personal or library account? Click to login
Mediating function of heart failure in the causal relationship between diastolic blood pressure and hypertensive renal disease with renal failure: a mediated Mendelian randomization study† Cover

Mediating function of heart failure in the causal relationship between diastolic blood pressure and hypertensive renal disease with renal failure: a mediated Mendelian randomization study†

Open Access
|Sep 2024

Figures & Tables

Figure 1.

Study design.

Note: IVW, inverse variance weighted; MR, Mendelian randomization.

Table 1.

Brief description for the GWAS data used in this study.

GWAS IDYearTraitConsortiumSample sizeNumber of SNPs
ieu-b-392018DBPInternational Consortium of Blood Pressure757,6017,160,619
ebi-a-GCST0095412020HFNA977,3237,773,021
ukb-b-37032018HAMRC-IEU462,9339,851,867
ukb-b-16682018AHDMRC-IEU463,0109,851,867
ukb-b-199552018HRDRFMRC-IEU463,0109,851,867

1 Note: AHD, atherosclerotic heart disease; DBP, diastolic blood pressure; HA, heart arrhythmia; HF, heart failure; HRDRF, hypertensive renal disease with renal failure.

Table 2.

Information on instrumental variables of DBP (201 SNPs).

SNPEAOAbetaeafchrpossep
rs10048404TC−0.10960.369418545784820.01832.00e–09
rs10054208TC0.11870.36175556889920.01851.49e–10
rs10279432AC0.11780.6234772790100.0185.73e–11
rs1035673CT−0.16250.603222.19e+080.01763.00e–20
rs1039897AG−0.10850.650322.2e+080.01833.26e–09
rs1049212GA0.17880.56941649329290.01751.30e–24
rs10759697AG0.13080.490691.17e+080.01733.93e–14
rs10804330CT−0.13310.432922.27e+080.01764.60e–14
rs10838702TG0.23750.387511474108880.01781.27e–40
rs10873612TC−0.10960.596115261056020.01799.51e–10
rs9368AC0.11210.387112569883420.01783.24e–10
rs9406076TC0.1010.3278680238040.01854.65e–08
rs9419374GA−0.11640.646101.34e+080.01853.44e–10
rs9526707AG−0.12170.322213514891860.01866.59e–11
rs964941AG0.17260.518312.28e+080.01743.31e–23
rs9791312CA0.12250.345261.43e+080.01842.89e–11
rs9841978AG0.17660.32513537307350.01851.12e–21
rs9889262AT0.22830.366617473980700.0187.11e–37
rs9900637AC0.09920.49611739519750.01761.73e–08
rs990619GC0.15920.523441.57e+080.01732.90e–20
rs9937801CT−0.15540.430816210881300.01744.81e–19

1 Note: DBP, diastolic blood pressure.

Table 3.

Information on instrumental variables of HF (394 SNPs).

SNPEAOAbetaeafchrpossep
rs10048404TC−0.10960.369418545784820.01832.00e–09
rs10054208TC0.11870.36175556889920.01851.49e–10
rs10062049TC0.22080.13595615538810.02554.50e–18
rs1006545TG0.36330.8875101.03e+080.02757.96e–40
rs10069690TC0.16150.2581512797900.0211.42e–14
rs10087280GA−0.13810.16838493918360.02322.54e–09
rs10164193GT0.21960.077718311614260.03271.87e–11
rs10279432AC0.11780.6234772790100.0185.73e–11
rs1035673CT−0.16250.603222.19e+080.01763.00e–20
rs1039897AG−0.10850.650322.2e+080.01833.26e–09
rs9508495TC−0.19440.756913301462010.02041.34e–21
rs9526707AG−0.12170.322213514891860.01866.59e–11
rs962369CT−0.16840.301311277344200.01896.02e–19
rs964941AG0.17260.518312.28e+080.01743.31e–23
rs9791312CA0.12250.345261.43e+080.01842.89e–11
rs9841978AG0.17660.32513537307350.01851.12e–21
rs9900637AC0.09920.49611739519750.01761.73e–08
rs9918907GA0.11880.216281.25e+080.0211.59e–08
rs9932220AG−0.15910.217716517581160.0213.76e–14
rs9937801CT−0.15540.430816210881300.01744.81e–19

1 Note: HF, heart failure.

Table 4.

Results of DBP on HRDRF and related indicators.

ExposureOutcomeIVWWME
OR95% CIP-valueOR95% CIP-value
DBPHRDRF1.00021.0001–1.00031.8076e–051.00021.0001–1.00041.1617e–03
DBPHF1.02951.0221–1.03702.5292e–151.03941.0300–1.04884.9222e–17
DBPHA1.00011.0000–1.000220.09321.00000.9999–1.000240.7875
DBPAHD1.00171.0014–1.00201.4957e–291.00171.0013–1.00201.1820e–20

1 Note: AHD, atherosclerotic heart disease; DBP, diastolic blood pressure; HA, heart arrhythmia; HF, heart failure; HRDRF, hypertensive renal disease with renal failure; IVW, inverse variance weighted.

Figure 2.

Schematic diagram of causality.

Figure 3.

(a) MR-estimated effects of DBP on each mediator separately, presented as β/OR with 95% CI. (b) MR-estimated effects of each mediator separately on HRDRF after MVMR adjustment for DBP, presented as β/OR with 95% CI. (c) MR estimated effects of indirect effects of each mediator separately, by product of coefficients method with delta method-estimated 95% CIs. MR estimated proportions mediated (%) are presented with 95% CIs.

Note: AHD, atherosclerotic heart disease; DBP, diastolic blood pressure; HA, heart arrhythmia; HF, heart failure; HRDRF, hypertensive renal disease with renal failure; MR, Mendelian randomization.

Table 5.

Mediation analysis results.

ExposureOutcomeOR95% CIP-value
HFHRDRF1.00171.0004–1.00300.0108

1 Note: HF, heart failure; HRDRF, hypertensive renal disease with renal failure.

Figure 4.

(A) MR effect size for DBP on HRDRF. (B) SNP effect on DBP. (C) MR funnel plot of DBP on HRDRF. (D) MR leave-one-out sensitivity analysis of DBP on HRDRF.

Note: DBP, diastolic blood pressure; HRDRF, hypertensive renal disease with renal failure; MR, Mendelian randomization.

DOI: https://doi.org/10.2478/fon-2024-0031 | Journal eISSN: 2544-8994 | Journal ISSN: 2097-5368
Language: English
Page range: 285 - 294
Submitted on: Feb 3, 2024
Accepted on: Apr 18, 2024
Published on: Sep 16, 2024
Published by: Shanxi Medical Periodical Press
In partnership with: Paradigm Publishing Services

© 2024 Lei Pang, Zi-Jun Ding, Hong-Qiang Chai, Fei Li, Ming Wu, Wei-Bing Shuang, published by Shanxi Medical Periodical Press
This work is licensed under the Creative Commons Attribution 4.0 License.